Aug. 7, 2025
FTC sues to block Edwards Lifesciences' $945M JenaValve deal
The agency argues the merger would eliminate the only meaningful competition in a market serving millions of Americans with aortic regurgitation, a potentially deadly heart condition.
The Federal Trade Commission sued Wednesday to block Irvine-based Edwards Lifesciences Corp.'s' $945 million acquisition of JenaValve Technology Inc., claiming the deal would eliminate competition and create a monopoly in the market for transcatheter aortic valve replacement (TAVR) devices used to treat aortic regurgitation.
Filed in the U.S. District Court for the District of Columbia, the FTC's complaint seeks a temporary restraining order and preliminary injunction ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In